Применение секукинумаба при нерентгенологическом аксиальном cпондилоартрите

Abstract

Since 2009, the concepts of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) have been used, while the radiographic phenotype (r-axSpA) and the non-radiographic phenotype (nr-axSpA) are distinguished. Nowadays, the treatment of nr-axSpA is carried out in the same way as r-axSpA. At the same time, it is obvious that nr-axSpA is more heterogeneous than radiographic, which can determine the peculiarities of patient management tactics. The authors cited 2 clinical cases in which they demonstrated the possibility of achieving persistent drug-free remission at an early (less than 6 months from the first occurrence of disease signs) use of secukinumab in patients with nr-axSpA. The clinical, laboratory and radiological data of two patients meeting the criteria of the SpondyloArthritis International Society are presented in detail. The clinical cases described in this paper are of considerable interest to practitioners since they present the first experience of using this drug in patients with nr-axSpA outside the clinical studies. Also, they can become a part of the clinical experience that will form the basis for further nraxSpA study with the subsequent development of individual clinical recommendations for the treatment of this disease. KEYWORDS: axial spondyloarthritis, non-radiographic axial spondyloarthritis, secukinumab, early treatment, remission. FOR CITATION: Gaydukova I.Z., Mazurov V.I., Inamova O.V. Secukinumab for non-radiographic axial spondyloarthritis. Russian Medical Inquiry. 2021;5(5):294–300 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-294-300.